Skip to content
DataLookout
Menu

NCT07908537

A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Progression-Free Survival (PFS)
Timeframe: Up to approximately 59 months

Secondary (10)

Overall Survival (OS)
Distant Metastasis-Free Survival (DMFS)
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Intervention Due to an AE
Mean Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 Item (EORTC QLQ-LC13) Cough (Items 31 and 32) Symptom Scale Score
Show 5 moreShow less
Mean Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Symptom Scale Score
Mean Change From Baseline in EORTC QLQ-LC13 Dyspnea (Items 33, 34, and 35) Symptom Scale Score
Time to Deterioration (TTD) in EORTC QLQ-LC13 Cough (Items 31 and 32) Symptom Scale Score
TTD in EORTC QLQ-LC13 Chest Pain (Item 40) Symptom Scale Score
TTD in EORTC QLQ-LC13 Dyspnea (Items 33, 34, and 35) Symptom Scale Score

Arms and interventions

Gocatamig and durvalumabExperimental

Participants will receive gocatamig and durvalumab until documented disease progression or discontinuation criteria are met.

DurvalumabActive comparator

Participants will receive durvalumab until documented disease progression or discontinuation criteria are met.

Biologicals: Gocatamig, Durvalumab

Drugs: Rescue Medications